Snowball logo
logo
ATE_logo

Antibe Therapeutics Inc.

ATE • TO
CA$0.295CA$0.00  (0%)
Estimate
EPS
-0.35
Beta
0.194
Forecast
EPS (FWD)
-0.45
About the company
Ticker
ATE
ISIN
CA0370255097
Country
Canada
Sector (GICS)
Healthcare
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Frequently asked questions

What sector does Antibe Therapeutics Inc. (ATE) operate in?

Antibe Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Antibe Therapeutics Inc. (ATE) current stock price?

As of the latest data, Antibe Therapeutics Inc. stock price is CA$0.30, with a previous close of CA$0.30.

What is Antibe Therapeutics Inc. (ATE) current market capitalization?

Antibe Therapeutics Inc. market cap is approximately 15.64 million.

What is Antibe Therapeutics Inc. (ATE) Earnings Per Share (EPS)?

The trailing EPS is -CA$0.35, and the forward EPS is -CA$0.45.

Does Antibe Therapeutics Inc. (ATE) pay dividends?

No. Antibe Therapeutics Inc. does not pay a dividend.

What is Antibe Therapeutics Inc. (ATE) beta (volatility) score?

Antibe Therapeutics Inc. has a beta of 0.194, indicating lower volatility than the overall market.